The use of mutant mycobacteria as new vaccines to prevent tuberculosis

Tuberculosis

Volumn 86, Issue 3-4 SPEC. ISS., 2006, Pages 203-210

  Hernandez Pando R ^a   Aguilar, L D ^a   Infante, E ^a   Cataldi, A ^b   Bigi, F ^b   Martin, C ^c   Gicquel, B ^d  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b INSTITUTO NACIONAL DE TECNOLOGÍA AGROPECUARIA INTA   (Argentina)

^c UNIVERSITY OF ZARAGOZA   (Spain)

^d INSTITUT PASTEUR   (France)

Author keywords

Mycobacterial mutants; Mycobacterium tuberculosis

Indexed keywords

AG 85; BACTERIAL ANTIGEN; BACTERIAL VACCINE; BCG VACCINE; ESAT 6; FADD 26; MYC 1551; MYC 1552; PHOP PROTEIN; PROBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIOPHAGE; CELLULAR IMMUNITY; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; HOMOLOGOUS RECOMBINATION; HUMAN; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOGENICITY; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; MOLECULAR BIOLOGY; MUTATION; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROPHYLAXIS; SURVIVAL; TH1 CELL; TUBERCULOSIS; VACCINATION;

ANIMALS; BCG VACCINE; DISEASE MODELS, ANIMAL; MUTAGENESIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, ATTENUATED;

EID: 33747874394     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2006.01.022     Document Type: Article

References (61)

1. Pablos-Mendez A., et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on anti-tuberculosis drug resistance surveillance. N Engl J Med 338 (1998) 1641-1649
2. Espinal M.A., et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on anti-tuberculosis drug resistance surveillance. N Engl J Med 344 (2001) 1294-1303
3. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 (1991) 1339-1345
4. Bardarov S., Kriakov J., Carriere C., Yu S., Vaamonde C., Mc Adam R.A., et al. Conditionally replicating mycobacteriophages: a system for transcriptase delivery to Mycobacterium tuberculosis. Proc Natl Acad Sci USA 94 (1997) 10965-10966
5. Pelicic V., Jackson M., Reyrat J.M., Jacobs W.R., Gicquel B., and Guilhot C. Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 94 (1997) 10955-10960
6. Cole S.T., Brosch R., Parkhill J., Garmier T., Chincher C., Harris D., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393 (1998) 537-544
7. Camacho L.R., Emsergueix D., Perez E., Gicquel B., and Guilhot C. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature tagged transposon mutagenesis. Mol Microbiol 34 (1999) 257-267
8. Cox J.S., Chen B., Mc Neil M., and Jacobs W.R. Complex lipid determines tissue specific replication of Mycobacterium tuberculosis in mice. Nature 402 (1999) 79-83
9. Smith D.A., Parish T., Stoker N.G., and Bancroft G.J. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun 69 (2001) 1142-1150
10. Behr M.A., Wilson M.A., Gill W.P., and Small P. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284 (1999) 1520-1523
11. Pinto R., Saunders B.M., Camacho L.R., Warwick J., Gicquel B., and Triccas J. Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacilli Calmette-Guerin vaccine. J Infect Dis 189 (2004) 105-112
12. Kolman A., and Ehrenberg L. Induction of a morphological mutant in Mycobacterium phlei by gamma-radiation and ethyl methanesulfonate. Ann Microbiol (Paris) 129 (1978) 127-130
13. Kundu M., Basu J., and Chakrabarti P. Defective mycolic acid biosynthesis in a mutant of Mycobacterium smegmatis. J Gen Microbiol 137 (1991) 2197-2200
14. Holland T., and Ratledge C. A procedure for selecting and isolating specific auxotrophic mutant of Mycobacterium semegmatis. J Gen Microbiol 6 (1971) 115-118
15. Hinshelwood S., and Stoker N.G. Cloning of mycobacterial histidine synthesis genes by complementation of a Mycobacterium smegmatis auxotroph. Mol Microbiol 6 (1992) 2887-2895
16. Jacobs Jr. W.R., Kalpana G.V., Cirillo J.D., Pascopella L., Snapper S.B., Udani R.A., et al. Genetic systems for mycobacteria. Methods Enzymol 204 (1991) 537-555
17. Pelicic V., Reyrat J.M., and Gicquel B. Genetic advances for studying Mycobacterium tuberculosis pathogenicity. Mol Microbiol 28 (1998) 413-420
18. Cavaignac S.M., White S.J., de Lisle G.W., and Collins D.M. Construction and screening of Mycobacterium paratuberculosis insertional mutant libraries. Arch Microbiol 173 (2000) 229-231
19. Guilhot C., Otal I., Van Rompaey I., Martin C., and Gicquel B.R. Efficient transposition in mycobacteria: construction of Mycobacterium smegmatis insertional mutant libraries. J Bacteriol 176 (1994) 535-539
20. Pelicic V., Jackson M., Reyrat J.M., Jacobs Jr. W.R., Gicquel B., and Guilhot C. Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 94 (1997) 10955-10960
21. Bardarov S., Kriakov J., Carriere C., Yu S., Vaamonde C., McAdam R.A., et al. Conditionally replicating mycobacteriophages: a system for transposon delivery to Mycobacterium tuberculosis. Proc Natl Acad Sci USA 30 94 (1997) 10961-10966
22. Berthet F.X., Lagranderie M., Gounon P., Laurent-Winter C., Ensergueix D., Chavarot P., et al. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science 282 (1998) 759-762
23. Fitzmaurice A.M., and Kolattukudy P.E. An acyl-CoA synthase (acoas) gene adjacent to the mycocerosic acid synthase (mas) locus is necessary for mycocerosyl lipid synthesis in Mycobacterium tuberculosis var. bovis BCG. J Biol Chem 273 (1998) 8033-8039
24. Parish T., Gordhan B.G., McAdam R.A., Duncan K., Mizrahi V., and Stoker N.G. Production of mutants in amino acid biosynthesis genes of Mycobacterium tuberculosis by homologous recombination. Microbiology 145 (1999) 3497-3503
25. Sander P., Meier A., and Bottger E.C. rpsL+: a dominant selectable marker for gene replacement in mycobacteria. Mol Microbiol 16 (1995) 991-1000
26. Parish T., and Stoker N.G. Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. Microbiology 146 (2000) 1969-1975
27. Rybniker J., Wolke M., Haefs C., and Plum G. Transposition of Tn5367 in Mycobacterium marinum, using a conditionally recombinant mycobacteriophage. J Bacteriol 185 (2003) 1745-1748
28. Bardarov S., Pavelka J., Sambandamurthy V., Larsen M., Tufariello J., Chan J., et al. Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. Microbiology 148 (2002) 3007-3017
29. Kamath A.T., Brennan M., Dobbelaer R., Hubrechts P., Ho M.M., Mayner R.E., et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 23 (2005) 3753-3761
30. López B., Aguilar L.D., Orozco H., Burger M., Espitia C., Ritacco V., et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin Exp Immunol 133 (2003) 30-37
31. Castañon Arreola M., Lopez Vidal Y., Espitia P.C., and Hernández Pando R. New vaccine against tuberculosis shows greater protection in a mouse model with progressive pulmonary tuberculosis. Tuberculosis 85 (2005) 115-126 [special edition: Tb vaccines for the world]
32. Infante E., Aguilar L.D., Gicquel B., and Hernández Pando R. Immunogenicity and protective efficacy of the Mycobacterium tuberculosis fadD26 mutant. Clin Exp Immunol 141 (2005) 21-28
33. Castillo-Rodal A., Castañón-Arreola M., Hernández-Pando R., Calva Mercado J., Sada D.E., and López-Vidal Y. BCG sub-strains confer different protection against Mycobacterium tuberculosis infection in BALB/c model of progressive pulmonary tuberculosis. Infect Immun. 74 (2006) 1718-1724
34. Power C.A., and Bretscher P.A. Mycobacterial doses define the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous or intradermal route. Infect Immun 66 (1998) 5743-5750
35. Aguilar LD, Infante E, Bianco MV, Cataldi A, Bigi F, Hernández Pando R. Immunogeniicity and protection induced by Mycobacterium tuberculosis mce-2 and mce-3 mutants in a Balb/c model of progressive pulmonary tuberculosis. Vaccine, in press.
36. Hernández Pando R., Pavón L., Arriaga K., Orozco E.H., Madrid M.V., and Rook G.A.W. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect Immun 6 (1997) 84-90
37. Hernández Pando R., Orozco E.H., Sampieri A., Pavón L., Velasquillo C., Larriva S.J., et al. Correlation between the kinetics of Th1/Th2 cells and pathology in a murine model of experimental pulmonary pathology. Immunology 89 (1996) 26-33
38. Hernández Pando R., Orozco E.H., Arriaga K., Sampieri A., Larriva S.J., and Madrid M.V. Analysis of the local kinetics and localization of interleukin 1 alpha, tumor necrosis factor alpha and transforming growth factor beta, during the course of experimental pulmonary tuberculosis. Immunology 90 (1997) 507-516
39. Hernández Pando R., Schön T., Orozco E.H., Serafin M., and Estrada G.I. Expression of nitric oxide synthase and nitrotyrosine during the evolution of experimental pulmonary tuberculosis. Exp Toxicol Pathol 53 (2001) 257-265
40. Seah G.T., Scott G.M., and Rook G.A. Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. J Infect Dis 181 (2000) 385-389
41. Seah G.T., and Rook G.A.W. High levels of mRNA encoding IL-4 in unstimulated peripheral blood mononuclear cells from tuberculosis patients revealed by quantitative nested RT-PCR; correlations with serum IgE levels. Scand J Infect Dis 33 (2000) 106-109
42. van Crevel R., Karyadi E., Preyers F., et al. Increased production of interleukin 4 by CD4+ and CD8+ T cells from patients with tuberculosis is related to the presence of pulmonary cavities. J Infect Dis 181 (2000) 1194-1197
43. Young D.B. Current tuberculosis vaccine development. Clin Infect Dis 30 Suppl. 3 (2000) S254-S256
44. Jackson M., Phalen S., Lagrenderie M., Ensergueix D., Chavarot P., Marchal G., et al. Persistence and protective efficacy of Mycobacterium tuberculosis auxotroph vaccine. Incet Immun 67 (1999) 2867-2873
45. Kanai K. Experimental studies on host-parasite equilibrium in tuberculosis infection, in relation to vaccination and chemotherapy. Jpn J Med Sci Biol 19 (1966) 181-199
46. Frankel F. Vaccines wake from the dead. Nat Med 11 (2005) 833-834
47. Chambers M., Williams A., Gavier-Widen D., Whelan A., Hall G., Marsh P., et al. Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin. Infect Immun 68 (2000) 7094-7099
48. Smith D., Parish T., Stoker N., and Bancroft G. Characterization of auxotrophic mutants of Mycobacterium tuberculosis as vaccine candidates. Infect Immun 69 (2001) 1142-1150
49. Andersen R. The chemistry of lipids of tubercle bacilli. Harvey Lect 35 (1940) 271-313
50. Sambandamurthy V.K., Wang X., Chen B., Russell R., Derrick S., Collins F., et al. Pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 8 (2002) 1171-1174
51. Sambandamurthy V.K., Derrick S., Jalapathy K.V., Chen B., Russell R.G., Morris S., et al. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect Immun 73 (2005) 1196-1203
52. Daffè M., and Lanèelle M.A. Distribution of phthiocerol diester, phenolic mycosides and related compounds in mycobacteria. J Gen Microbiol 134 (1988) 2049-2055
53. Trivedl O.A., Arora P., Sridharan V., Tickoo R., Mohanty D., and Gokhale R. Enzymic activation and transfer of fatty acids as acyl-adenylates in mycobacteria. Nature 428 (2004) 441-445
54. Camacho L.R., Constant P., Raynaud C., Lanèelle M.A., Triccas J.A., and Gicquel B. Analysis of the phthiocerol dimycocerosate locus of Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall permeability. J Biol Chem 276 (2001) 19845-19854
55. Rousseau C., Winter N., Pivert E., Bordat Y., Neyrolles O., Ave P., et al. Production of phthiocerol dimycocerosates protects Mycobacterium tuberculosis from the cidal activity of reactive nitrogen intermediates produced by macrophages and modulates the early immune response to infection. Cell Microbiol 6 (2004) 277-287
56. Arruda S., Bomfim G., Knights R., Huima-Byron T., and Riley L. Cloning an M. tuberculosis DNA fragment associated with entry and survival inside cells. Science 261 (1993) 1454-1457
57. Gioffre A., Infante E., Aguilar D., Santangelo M.P., Klepp L., Amadio A., et al. Mutation in mce genes attenuate M. tuberculosis virulence. Microbes Infect 7 (2005) 325-334
58. Soto C.Y., Menendez M.C., Perez E., Samper S., Gomez A.B., Garcia M.J., et al. IS6110 mediates increased transcription of the phoP virulence gene in a multidrug-resistant clinical isolate responsible for tuberculosis outbreaks. J Clin Microbiol 42 (2004) 212-219
59. Fields P.I., Groisman E.A., and Heffron F. A Salmonella locus that controls resistance to microbicidal proteins from phagocytic cells. Science 243 (1989) 1059-1062
60. Groisman E.A. The pleiotropic two-component regulatory system PhoP-PhoQ. J Bacteriol 183 (2001) 1835-1842
61. Perez E., Samper S., Bordas Y., Guilhot C., Gicquel B., and Martin C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol 41 (2001) 179-187